СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes

Aim: To determine frequency of tumors with immunohistochemical markers of cancer stem cells (CSC) CD44+/CD24− in patients with breast cancer (BC) of different molecular subtype and to evaluate their prognostic value. Object: Surgical material of 132 patients with BC stage I–II, age from 23 to 75 yea...

Full description

Saved in:
Bibliographic Details
Published in:Experimental Oncology
Date:2015
Main Authors: Chekhun, S.V., Zadvorny, T.V., Tymovska, Yu.O., Anikusko, M.F., Novak, O.E., Polishchuk, L.Z.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2015
Subjects:
Online Access:https://nasplib.isofts.kiev.ua/handle/123456789/145447
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Cite this:СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes / S.V. Chekhun, T.V. Zadvorny, Yu.O. Tymovska, M.F. Anikusko, O.E. Novak, L.Z. Polishchuk // Experimental Oncology. — 2015. — Т. 37, № 1. — С. 58-63. — Бібліогр.: 38 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-145447
record_format dspace
spelling Chekhun, S.V.
Zadvorny, T.V.
Tymovska, Yu.O.
Anikusko, M.F.
Novak, O.E.
Polishchuk, L.Z.
2019-01-21T21:21:18Z
2019-01-21T21:21:18Z
2015
СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes / S.V. Chekhun, T.V. Zadvorny, Yu.O. Tymovska, M.F. Anikusko, O.E. Novak, L.Z. Polishchuk // Experimental Oncology. — 2015. — Т. 37, № 1. — С. 58-63. — Бібліогр.: 38 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145447
Aim: To determine frequency of tumors with immunohistochemical markers of cancer stem cells (CSC) CD44+/CD24− in patients with breast cancer (BC) of different molecular subtype and to evaluate their prognostic value. Object: Surgical material of 132 patients with BC stage I–II, age from 23 to 75 years, mean age — 50.2 ± 3.1 years was studied. Methods: Clinical, immunohistochemical (expression CD44+/CD24−), morphological, statistical. Results: BC is characterized by heterogeneity of molecular subtypes and expression of markers (CD44+/CD24−). Immunohistochemical study of expression of CSC markers in surgical material has detected their expression in 34 (25.4%) patients with BC of different molecular subtypes. The highest frequency of cells with expression of CSC marker was observed in patients with basal molecular subtype (44.8% patients). Most of BC patients with phenotype CD44+/CD24 had stage I of tumor process (34.3%). Statistical processing of data has showen that Yule colligation coefficient equaled 0.28 (р > 0.05) that argues poor correlation between stage of tumor process and number of tumors with positive expression of CSC markers. Statistical processing of data has showen high correlation between presence of cells with expression of CSC markers and metastases of BC in regional lymph nodes (Yule colligation coefficient equals 0.943; р < 0.5). Difference in overall survival of patients with BC of basal molecular subtype depending on expression of CSC CD44+/CD24− markers was detected. Survival of patients with basal BC was reliably higher at lack in tumors of cells with CSC markers CD44+/CD24− and, correspondingly, lower at presence of such cells (р < 0.05). In patients with BC of luminal (A and B), HER-2-positive subtypes, significant change in survival of patients depending on expression of CSC markers was not determined (р > 0.05). Conclusion: Significance of tumor cells with markers CD44+/CD24− within the limits of molecular subtype of BC may be additional criterion for advanced biological characteristic of BC, and in patients with BC of basal molecular subtype — for predictive evaluation of individual potential of tumor to aggressive clinical course. Key Words: breast cancer, cancer stem cells, СD44+/CD24−, molecular subtype.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
spellingShingle СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
Chekhun, S.V.
Zadvorny, T.V.
Tymovska, Yu.O.
Anikusko, M.F.
Novak, O.E.
Polishchuk, L.Z.
Original contributions
title_short СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
title_full СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
title_fullStr СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
title_full_unstemmed СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
title_sort сd44+/cd24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes
author Chekhun, S.V.
Zadvorny, T.V.
Tymovska, Yu.O.
Anikusko, M.F.
Novak, O.E.
Polishchuk, L.Z.
author_facet Chekhun, S.V.
Zadvorny, T.V.
Tymovska, Yu.O.
Anikusko, M.F.
Novak, O.E.
Polishchuk, L.Z.
topic Original contributions
topic_facet Original contributions
publishDate 2015
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Aim: To determine frequency of tumors with immunohistochemical markers of cancer stem cells (CSC) CD44+/CD24− in patients with breast cancer (BC) of different molecular subtype and to evaluate their prognostic value. Object: Surgical material of 132 patients with BC stage I–II, age from 23 to 75 years, mean age — 50.2 ± 3.1 years was studied. Methods: Clinical, immunohistochemical (expression CD44+/CD24−), morphological, statistical. Results: BC is characterized by heterogeneity of molecular subtypes and expression of markers (CD44+/CD24−). Immunohistochemical study of expression of CSC markers in surgical material has detected their expression in 34 (25.4%) patients with BC of different molecular subtypes. The highest frequency of cells with expression of CSC marker was observed in patients with basal molecular subtype (44.8% patients). Most of BC patients with phenotype CD44+/CD24 had stage I of tumor process (34.3%). Statistical processing of data has showen that Yule colligation coefficient equaled 0.28 (р > 0.05) that argues poor correlation between stage of tumor process and number of tumors with positive expression of CSC markers. Statistical processing of data has showen high correlation between presence of cells with expression of CSC markers and metastases of BC in regional lymph nodes (Yule colligation coefficient equals 0.943; р < 0.5). Difference in overall survival of patients with BC of basal molecular subtype depending on expression of CSC CD44+/CD24− markers was detected. Survival of patients with basal BC was reliably higher at lack in tumors of cells with CSC markers CD44+/CD24− and, correspondingly, lower at presence of such cells (р < 0.05). In patients with BC of luminal (A and B), HER-2-positive subtypes, significant change in survival of patients depending on expression of CSC markers was not determined (р > 0.05). Conclusion: Significance of tumor cells with markers CD44+/CD24− within the limits of molecular subtype of BC may be additional criterion for advanced biological characteristic of BC, and in patients with BC of basal molecular subtype — for predictive evaluation of individual potential of tumor to aggressive clinical course. Key Words: breast cancer, cancer stem cells, СD44+/CD24−, molecular subtype.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/145447
citation_txt СD44+/CD24− markers of cancer stem cells in patients with breast cancer of different molecular subtypes / S.V. Chekhun, T.V. Zadvorny, Yu.O. Tymovska, M.F. Anikusko, O.E. Novak, L.Z. Polishchuk // Experimental Oncology. — 2015. — Т. 37, № 1. — С. 58-63. — Бібліогр.: 38 назв. — англ.
work_keys_str_mv AT chekhunsv sd44cd24markersofcancerstemcellsinpatientswithbreastcancerofdifferentmolecularsubtypes
AT zadvornytv sd44cd24markersofcancerstemcellsinpatientswithbreastcancerofdifferentmolecularsubtypes
AT tymovskayuo sd44cd24markersofcancerstemcellsinpatientswithbreastcancerofdifferentmolecularsubtypes
AT anikuskomf sd44cd24markersofcancerstemcellsinpatientswithbreastcancerofdifferentmolecularsubtypes
AT novakoe sd44cd24markersofcancerstemcellsinpatientswithbreastcancerofdifferentmolecularsubtypes
AT polishchuklz sd44cd24markersofcancerstemcellsinpatientswithbreastcancerofdifferentmolecularsubtypes
first_indexed 2025-12-07T16:57:48Z
last_indexed 2025-12-07T16:57:48Z
_version_ 1850869462030352384